Question 1

What is Cerebrolysin?

Accepted Answer

Cerebrolysin is a hospital preparation made from pig brain, and it is given through a vein over a course of days rather than taken as a pill. It is not a single molecule, which sets it apart from almost every other compound on this site. A 2009 review describes it as a parenterally administered, porcine brain-derived peptide preparation, meaning it is given by injection and comes from pig brain. The 2019 Cochrane review of vascular dementia adds how that is usually done: as a series of daily intravenous infusions. A 2014 cell study names the maker as EVER Neuro Pharma GmbH, Austria, and calls it indicated for clinical use in stroke, traumatic brain injury and dementia. Those three conditions hold almost all of its human research. They are also where the arguments about it take place, and the rest of this page follows them in turn.

Question 2

What is Cerebrolysin made of?

Accepted Answer

It is a mixture of small protein fragments and loose amino acids, the building blocks those fragments are made from. The Cochrane stroke reviews describe it as a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue. A 2018 spine trial puts the split at 85% free amino acids and 15% biologically active low-molecular weight peptides. A mixture taken from tissue cannot be written down as one formula, the way a synthetic peptide can. What it contains is defined by how it is made. A 2023 Russian-language review makes that point itself, saying very strict measures are taken in production to keep quality and identity steady from batch to batch. Similar mixtures exist, and the 2023 Cochrane stroke update added one RCT of Cerebrolysin-like agent Cortexin to its analysis. So the name refers to one maker's preparation rather than to a molecule that anyone could copy exactly.

Question 3

What is Cerebrolysin used for?

Accepted Answer

In the countries where it is used, it is mainly a hospital treatment for stroke, with brain injury and dementia close behind. The Cochrane stroke reviewers report it is widely used for acute ischaemic stroke in Russia, Eastern Europe, China, and other Asian and post-Soviet countries. A 2018 stroke review puts its current use more broadly, as cerebral ischemia and neurodegeneration, meaning loss of blood flow to the brain and the slow loss of brain cells. For dementia, the 2019 Cochrane review notes that in many parts of the world it is used as a potential intervention for vascular dementia. Smaller trials have tried it in motor neurone disease, multiple sclerosis, a spinal cord condition and premature babies, and those results are laid out one by one at the Cerebrolysin benefits page. Widely used is a statement about prescribing habits in particular countries. It does not mean the same thing as shown to work, and the next four sections take those two apart.

Question 4

Does Cerebrolysin actually work?

Accepted Answer

It depends on which condition you ask about and which review you read, and the reviews of the same trials have reached opposite conclusions. A 2021 review of stroke, brain injury and dementia found inconsistent results, with several clinical studies suggesting minor clinical relevance and no significant advantage over a placebo. A 2019 stroke-care review took the other side, calling drugs like cerebrolysin valid options for adjunctive treatment of acute ischemic stroke, meaning given on top of standard care. A 2017 commentary on the stroke trials put its view in its title: Evidence Again Fails to Support a Neuroprotectant. Both camps are reading mostly the same trials. What separates them is which trials they let in, which outcome they count, and who ran the analysis. The sections below go condition by condition and report what each review concluded, and in whom, rather than picking a winner.

Question 5

What did the stroke reviews conclude, and in whom?

Accepted Answer

Stroke is where the evidence is largest, and it is also where the split between reviews is sharpest. The 2023 Cochrane update pooled seven RCTs with 1773 participants, all in acute ischaemic stroke and started within 48 hours of onset, one of them testing the look-alike mixture Cortexin. It concluded that Cerebrolysin or similar mixtures probably have no beneficial effect on preventing all-cause death. None of the included studies reported on poor functional outcome, defined as death or dependence, so it could not say whether survivors were left less disabled. A 2017 meta-analysis of six RCTs and 1,649 patients found no significant effect on functional recovery at day 90. A 2018 meta-analysis of nine trials, which counted neurological deficit at around day 30, reported superiority over placebo across 1,879 patients. A 2021 European neurology and rehabilitation guideline went further and recommended it for clinical use in early rehabilitation after ischaemic stroke. Look at what each one measured. Cochrane looked mainly at death and serious harm, while the positive analyses looked at symptom scores in the first weeks. A modest early change on a stroke scale does not mean fewer deaths, and no difference in deaths does not rule out a change in recovery.

Question 6

What did the dementia reviews conclude?

Accepted Answer

The dementia record reads more favourably than the stroke record. It also rests on fewer and smaller trials, and that matters more than the headline. Vascular dementia is the kind caused by damage to the brain's blood supply, and the 2019 Cochrane review of it found six randomised trials with 597 people in total. It found better thinking and general function in the trial participants, but it called the evidence base weak. Any effects, it warned, may be too small to be clinically meaningful. For Alzheimer's disease, a 2015 pooling of six placebo-controlled trials found an overall benefit in patients with mild to moderate disease. A 2022 umbrella review, which pools other reviews, put it beside donepezil-type drugs and Ginkgo biloba as appearing beneficial in Alzheimer's disease. A 2025 review of 173 trials in vascular memory loss found small to moderate improvements in cognition, but it rated the certainty of the evidence low. Small, short and positive is a different thing from established. These trials took people with mild to moderate disease, and most of them ran for weeks rather than years.

Question 7

What did the brain-injury reviews conclude?

Accepted Answer

Brain injury has the fewest randomised trials of the three conditions, and yet it has the largest pooled number. That odd pairing is worth a closer look. A 2023 meta-analysis pooled ten studies and 8749 patients, and it mixed studies that looked back at records with studies that followed people forward. It found a real change on the Glasgow scales, which grade consciousness and recovery after injury. Death from any cause and the length of the hospital stay did not change. The randomised core is much smaller, and the two CAPTAIN placebo trials together covered 185 patients, with a small-to-medium sized effect in favour of Cerebrolysin. A 2025 review of brain-injury care still lists it among agents being tested, in a field it says has not yielded any viable therapeutic options to date. A retrospective study, one that looks back through hospital records, cannot rule out that the patients given infusions differed from the others before anything was given. A large pooled figure built partly from such studies is therefore weaker than it appears.

Question 8

Why do the reviews disagree?

Accepted Answer

Two explanations run through the literature, and they point in opposite directions. The Cochrane stroke authors note that the manufacturer supported three multi-centre studies, either totally or by providing the infusions and placebo, randomisation codes, research grants or statisticians. In vascular dementia, the Cochrane review found that where funding was reported, all studies were supported by the pharmaceutical industry. A 2018 review offers the other explanation: early stroke trials enrolled mostly mildly affected patients, who usually recover well anyway, leaving little room to show a difference. Neither explanation proves the other side wrong. Industry support is a reason to read a trial closely rather than a reason to discard it. The severity argument is drawn after the fact from subgroups, and that is the weakest kind of positive result. Who benefited most in those subgroups is set out at the Cerebrolysin benefits page.

Question 9

How far has Cerebrolysin been tested in people?

Accepted Answer

Further than most compounds on this site. Randomised trials go back more than three decades, and the open-label registries run to well over a thousand patients. The earliest randomised trial among the research behind this page dates from 1990, when elderly patients with moderate cognitive impairment received a series of ten Cerebrolysin and multivitamin infusions against multivitamins alone. The largest single study, the C-REGS2 registry, ran in 16 countries and covered 1769 stroke patients, 1021 of them given Cerebrolysin. That registry was open-label, meaning patients and doctors knew who received what. Trials still in progress include one in critically ill patients with delirium, listed as enrolling by invitation. That is a large human record. Size is not the problem with it. The difficulty is that the biggest studies are the least controlled, while the best-controlled ones are small or neutral.

Question 10

How is Cerebrolysin given?

Accepted Answer

Almost always as a drip into a vein, in hospital, measured in millilitres of solution and given daily over a course of days or weeks. A 2002 Alzheimer's trial is typical, with patients injected intravenously with placebo or 30 mL five days per week for four weeks. A 2013 Russian-language trial in young children with a speech disorder used injections into muscle instead, every other day. The amounts, schedules and repeat courses in each condition are set out trial by trial at the Cerebrolysin dosage page, as study parameters rather than guidance.

Question 11

Is Cerebrolysin FDA-approved?

Accepted Answer

No, according to the one source behind this page that addresses it directly. A 2021 review states that although Cerebrolysin is not approved for use in the USA, it is used clinically in over 50 countries worldwide. Papers from the stroke trial programme describe it as approved for stroke, without naming the countries. A 2023 brain-injury review likewise calls it a drug approved for use in patients diagnosed with TBI. An approval in one country is a fact about that country's regulator, and it does not carry across a border. None of the abstracts behind this page names which regulators approved it, so we cannot list them.

Question 12

Why isn't Cerebrolysin approved in the US, and is it available there?

Accepted Answer

None of the papers behind this page explains why it has no US approval, and we will not guess at a regulator's reasoning. What the record does show is the evidence a regulator would be weighing: Cochrane stroke reviews that found no survival benefit, dementia reviews that found benefit on low-quality evidence, and trials often supported by the manufacturer. On availability, the FDA enforcement records we found hold two Class II recalls of Cerebrolysin injections labelled by US firms, both for lack of sterility assurance. A recall is a record that a batch of injections could not be shown to be sterile. It says nothing about whether the compound works, and it is not an approval in reverse. The firms, dates and vial labels are taken apart at the Cerebrolysin safety page.

Question 13

Is Semax the same as Cerebrolysin?

Accepted Answer

No. Semax is a separate compound with its own body of work, covered at the Semax overview. Nothing among the research behind this page tests the two side by side, or treats one as a form of the other, and the same goes for the Selank overview. The closer question is whether other brain-derived mixtures can stand in for Cerebrolysin. Here the sources do have something to say. A 2024 study tested several peptide mixtures said to be similar to Cerebrolysin and approved in some countries. It found that they lack relevant biological activity and that their peptide make-up is very different from Cerebrolysin. That was a lab comparison of look-alikes against the original, and it ran in a journal that has also published several of the clinical trials. Read it as one side's measurement rather than as the last word.

Question 14

What does the Cerebrolysin safety record show, in brief?

Accepted Answer

What is on record comes from real placebo trials, which is more than most compounds in this category can show. The reviews of those trials split over one kind of harm. A 2017 pooling of seven stroke trials and 1779 patients found that, on safety, it looked much like placebo, including on deaths and serious events. The 2023 Cochrane update saw it differently, and reported moderate-certainty evidence of a possible rise in non-fatal serious adverse events. The common side effects, the allergic reaction on record, the liver question and the US recalls are taken one at a time at the Cerebrolysin safety page.

Question 15

How is Cerebrolysin thought to work?

Accepted Answer

The proposed idea is that it behaves like the body's own nerve growth signals. A 2012 review describes it as a peptide preparation that mimics the pleiotropic effects of neurotrophic factors, the proteins that keep nerve cells alive and help them grow. A 2023 review adds that it has been shown to resemble the activities of these factors and to change how much of them the body makes. Where that account comes from matters, and a 2012 pharmacology review is explicit that its summary draws on in vitro assays and in vivo animal models. A plausible mechanism in cells and rats explains why trials were run. It does not tell you what the trials found, and the deeper laboratory work is at the Cerebrolysin benefits page.

Cerebrolysin